<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392898</url>
  </required_header>
  <id_info>
    <org_study_id>Lir-HJCJ-03</org_study_id>
    <nct_id>NCT01392898</nct_id>
  </id_info>
  <brief_title>Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes</brief_title>
  <acronym>ELEGANT</acronym>
  <official_title>The Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Insulin therapy is frequently needed to achieve adequate glycaemic control in type 2&#xD;
      diabetes. Although insulin is an effective treatment modality, this is often at the expense&#xD;
      of significant weight gain. Weight gain is obviously undesirable in an already overweight&#xD;
      population, but may also deter further optimization of insulin therapy. Large&#xD;
      inter-individual differences exist in the level of weight gain after initiation of insulin&#xD;
      therapy, but no clear predictive factors have prospectively been identified thus far.&#xD;
&#xD;
      Liraglutide (Victoza®), a human glucagon-like peptide-1 (GLP-1) analogue, improves glycaemic&#xD;
      control and reduces weight. We hypothesize that in patients who show (excessive) weight gain&#xD;
      after introducing insulin therapy, adding liraglutide is effective in reversing body weight&#xD;
      while preserving glycaemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes mellitus on short-term (≤ 12 months) insulin therapy with&#xD;
      concomitant documented weight gain of ≥ 4 % body weight will be selected and treated with&#xD;
      liraglutide 1.8 mg sc q.d. for 26 weeks and compared to patients receiving standard care&#xD;
      (continuation of insulin therapy without liraglutide) in an open-label, randomized study.&#xD;
      After 26 weeks, patients receiving standard care will subsequently be treated with&#xD;
      liraglutide for 26 weeks. The group on active liraglutide treatment will continue for an&#xD;
      additional 26 weeks. In this way all patients can benefit from liraglutide.&#xD;
&#xD;
      All subjects will continue insulin therapy and oral hypoglycaemic agents (SU derivatives and&#xD;
      metformin allowed) treatment. With respect to safety in order to avoid hypoglycaemic events,&#xD;
      total insulin dose will be decreased by 20% when starting liraglutide. Within the first weeks&#xD;
      after start of study medication patients will perform frequently self-measured capillary&#xD;
      blood glucose profiles and will be instructed to adjust insulin dose if necessary. Initially,&#xD;
      insulin dose will be adjusted weekly by telephone consultation. Thereafter, patients will&#xD;
      perform blood glucose profiles prior to every outpatient visit. A liraglutide-insulin&#xD;
      titration algorithm will be used to adjust insulin dose. Every 4-6 weeks patients will visit&#xD;
      the hospital to assess body weight, to adjust insulin dose and to check for adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight change (measured body weight at 26 weeks minus baseline body weight)</measure>
    <time_frame>26 weeks (26 weeks - baseline)</time_frame>
    <description>Measuring body weight after 26 weeks minus baseline body weight as the change in body weight after Liraglutide treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring change in insulin dose (insulin dose at 26 weeks minus insulin dose at baseline)</measure>
    <time_frame>26 weeks (26 weeks -baseline)</time_frame>
    <description>Change in insulin dose by measuring insulin dose at 26 weeks minus the insulin dose at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>liraglutide 1.8 mg q.d.</description>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>insulin dosed according titration scheme</description>
    <arm_group_label>insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus on short-term insulin therapy (≤ 12 months);&#xD;
             all types of insulin allowed&#xD;
&#xD;
          -  Documented insulin-associated weight gain ≥ 3.0 kg from the start of insulin therapy&#xD;
             until inclusion&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  BMI ≥ 25 kg/m2&#xD;
&#xD;
          -  Stable glycaemic control mirrored by HbA1c ≥ 6.5 and ≤ 8.5 %&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Type 1 diabetes mellitus, MODY diabetes, or LADA diabetes (presence of anti-GAD)&#xD;
&#xD;
          -  Presence of any medical condition that might interfere with the current study&#xD;
             protocol.&#xD;
&#xD;
          -  Inflammatory bowel disease (e.g. M. Crohn, ulcerative colitis)&#xD;
&#xD;
          -  Recurrent hypoglycaemic events&#xD;
&#xD;
          -  Diabetic gastroparesis&#xD;
&#xD;
          -  Heart failure (LVEF ≤ 30%)&#xD;
&#xD;
          -  Use of TZDs (glitazones), DDP-IV (dipeptidylpeptidase-inhibitor)&#xD;
&#xD;
          -  Use of medication associated with impaired glucose metabolism including&#xD;
             corticosteroids&#xD;
&#xD;
          -  Pregnancy or breast-feeding (contraception of at least 3 months before inclusion is&#xD;
             required for fertile women)&#xD;
&#xD;
          -  Pre-existing thyroid disease&#xD;
&#xD;
          -  Liver disease (aspartate aminotransferase or alanine aminotransferase level of more&#xD;
             than three times the upper limit of normal range)&#xD;
&#xD;
          -  Renal disease (creatinine &gt; 130 µmol/l or MDRD-GFR &lt;30 ml/min/1.73m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 4, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liraglutide</keyword>
  <keyword>insulin</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

